✦ LIBER ✦

PCN6: MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ Scribed by P Sharplin; UK Bose; J Holmes

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN100 COST-EFFECTIVENESS OF GEFITINIB V

✍ J Jacob; M Henriksson; D Brattström 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Docetaxel and carboplatin combination as

✍ J.W.G. Van Putten; F.M. Wachters; H.J.M. Groen 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Phase II trial of weekly docetaxel (D) i

✍ Lilenbaum, R; Schwartz, M; Siegel, L; Belette, F; Blaustein, A; Wittlin, F; Cisn 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

PCN104 COST-EFFECTIVENESS OF ERLOTINIB I

✍ W Chen; F Sheng; N Qiao 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Cost-effectiveness analysis of pemetrexe

✍ Yumi Asukai; Amparo Valladares; Carlos Camps; Eifiona Wood; Kaisa Taipale; Jorge 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 781 KB